Coloplast completes the acquisition of Kerecis - Seite 2

“We look forward to continuing our strong growth trajectory as part of Coloplast. Kerecis can leverage Coloplast’s expertise, capabilities, and industry-leading infrastructure to secure the long-term success of our company and become a category leader in the biologics segment. I would like to thank everyone at Kerecis for a fantastic journey so far, and I look forward to entering the next chapter together and reaching many more patients with our patented technology based on intact fish skin” says Fertram Sigurjonsson, founder and CEO of Kerecis, who will continue to lead the Kerecis team.

As a result of the agreement to acquire Kerecis, Coloplast raised its long-term organic growth guidance to 8-10%, from previously 7-9%, on July 7, 2023. The long-term EBIT margin guidance was maintained at above 30% beyond FY 2024/25. The EBIT margin is expected to remain below 30% in the Strive25 strategic period and includes around 100 basis points dilution p.a. from Kerecis (incl. PPA amortisation). Kerecis has an attractive gross margin level, accretive to Coloplast’s gross margin, and thus strong potential to expand its profitability driven by continued growth and scalability. The transaction is expected to be increasingly EPS accretive from FY 2026/27.

For further details on the acquisition of Kerecis, please refer to stock exchange announcement no. 03/2023 from July 7, 2023 (Coloplast announces agreement to acquire Kerecis). For more information on the completion of the equity capital raise related to the financing of the acquisition, please refer to stock exchange announcement no. 07/2023 from August 30, 2023 (Equity Issue of B Shares (coloplast.com)). For details on the financial guidance for FY 2022/23, please refer to announcement no. 04/2023, Interim Financial Report for 9M 2022/23 (9M 22/23 Earnings Release (coloplast.com)).

Investor and analyst conference call with Fertram Sigurjonsson, founder and CEO of Kerecis
Coloplast will host a conference call on September 4, 2023, at 14.00h CEST. On the call, Kristian Villumsen, CEO and President, and Anders Lonning-Skovgaard, CFO and EVP, will be joined by Fertram Sigurjonsson, founder and CEO of Kerecis.

Access the conference call webcast directly here: Coloplast conference call (getvisualtv.net)
To actively participate in the Q&A session, please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Diamond Pass Registration (choruscall.it)